HealthCare Global Enterprises Limited has finalized a share purchase agreement to sell its entire stake in BACC Health Care Private Limited to Inviga Healthcare Fund I for a total consideration of INR 37.64 crore. The move aligns with the company’s strategic goal of focusing on its core oncology and healthcare services, as the divested unit operates in the fertility and reproductive health space, which is considered non-core to its primary business operations.
Transaction Details
On May 19, 2026, HealthCare Global Enterprises Limited signed a definitive agreement to divest its entire shareholding in BACC Health Care Private Limited. The buyer, Inviga Healthcare Fund I, will acquire the unit for a total consideration of INR 37,64,44,788. The transaction is expected to conclude within 4-5 weeks from the date of the agreement.
Payment Structure
The total consideration will be settled in two tranches. An initial payment of INR 28,23,33,591 will be received upon the closing date of the transaction. The remaining deferred consideration of INR 9,41,11,197 is scheduled to be paid within 18 months of signing the agreement. The company has clarified that this deferred payment is not subject to any conditional or contingent terms.
Strategic Rationale and Oversight
The decision to divest follows a competitive process initiated by the company to streamline its portfolio. The fertility and reproductive healthcare services offered by the unit are not part of the company’s core business activities. The transaction is classified as a related party deal, as the fund is controlled by Dr. B.S. Ajaikumar, the Promoter and Non-Executive Chairman of the company. To ensure transparency, the deal was finalized at an arm’s length basis, supported by a valuation report from an independent third-party valuer.
Financial Contribution
For the 2025-26 financial year, the BACC unit recorded revenue from operations of INR 60.45 crore, representing approximately 4.45% of the company’s standalone revenue. The unit’s net worth stood at INR 17.53 crore as of March 31, 2026, accounting for 1.09% of the company’s total standalone net worth.
Source: BSE
